Literature DB >> 12857059

Urethral recurrence following neobladder in bladder cancer patients.

Shinichi Yamashita1, Senji Hoshi, Chikara Ohyama, Makoto Satoh, Fumihiko Soma, Yasuhiro Okada, Shinnosuke Kato, Ichiro Shintaku, Yoichi Arai.   

Abstract

Risk factors of urethral recurrence after neobladder in bladder cancer patients were studied. Between 1977 and 2001, 73 patients (male 58, female 15) underwent neobladder as a treatment for bladder cancer. The observation time after cystectomy ranged from 2 to 254 months (median 60.5). Ten (17.2%) of 58 male patients had urethral recurrence and of the 10, 8 patients had multiple bladder cancers including bladder neck. Urethral recurrence was found by macrohematuria, follow-up cystourethroscopy, and inguinal lymph node swelling. Only one who complained of macrohematuria had positive urinary cytology. Of 58 male patients, 5 underwent total nephroureterectomy for renal pelvic or ureteral cancer before radical cystectomy, and 3 of the 5 had urethral recurrence. Two of 10 patients with urethral recurrence died with cancer, and they had renal pelvic or ureteral cancer. The five-year cause specific survival was 83% for patients with urethral recurrence, and 79% for those without urethral recurrence, respectively. Urethral recurrence did not have a significant effect on survival. The patients with multiple bladder cancers including bladder neck, and renal pelvic or ureteral cancer before radical cystectomy, have high risks for urethral recurrence. Urinary cytology has limited value for the detection of urethral recurrence.

Entities:  

Mesh:

Year:  2003        PMID: 12857059     DOI: 10.1620/tjem.199.197

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  1 in total

1.  Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer: a meta-analysis of 9498 patients.

Authors:  Xinyuan Li; Wuwan Wang; Gongmin Zhu; Weiyang He; Xin Gou
Journal:  Oncotarget       Date:  2017-12-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.